Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.

By Johann de Bono, S. Oudard, M. Ozguroglu, S. Hansen, J. Machiels, I. Kocák, G. Gravis, I. Bodrogi, Mary J. MacKenzie, L. Shen and 3 more. The Lancet, 2010

3,174 citations recorded by the source corpus.

Subfields: Psychiatry and Mental health, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/1289978ff58f2759eaa73e478538635db41fd874

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Pulmonary and Respiratory Medicine

1. M. Hallek
2. Michel Bolla
3. N. Mottet
4. J. Bellmunt
5. Steven Joniau
6. Thomas Wiegel

Citations in the corpus

• Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy (2017, neutral): “(%) No 50 (5) 61 (6) Short‐term antiandrogen 902 (94) 895 (93) Long‐term antiandrogen 5 (1) 4 (<1) Radiotherapy planned — no.”
• EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer. (2017, background): “It was studied in a large prospective randomised phase 3 trial (TROPIC trial) comparing cabazitaxel plus prednisone versus mitoxantrone plus prednisone in 755 patients with mCRPC who had progressed after or during docetaxel-based chemotherapy [90].”
• Genetics and biology of prostate cancer (2018, background): “Another chemotherapy agent, cabazitaxel, was approved in 2010 for mCRPC patients previously treated with docetaxel and in 2017 for use at a lower dosage based on the results of two phase 3 randomized trials (de Bono et al. 2010; Sartor et al. 2016).”
• EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II-2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer. (2020, background): “It was studied in a large prospective, randomised, phase III trial (TROPIC trial) comparing cabazitaxel plus prednisone versus mitoxantrone plus prednisone in 755 patients with mCRPC, who had progressed after or during docetaxel-based chemotherapy [120].”
• Prostate Cancer (2018, background): “The initial study from biopsy-derived tumor tissue included 349 patients who were managed conservatively following cancer diagnosis [12].”